US and EU are closely harmonized in terms of their requirements, so no additional study is needed in EU. China is different though. In addition to R-IT, Amarin needs a China specific study to show the drug is safe and effective in Chinese population. I assume this is the study that began in Jan 2018.
After that study concludes, Amarin will submit both R-IT and China specific study in their China NDA for V.
Market Data 
Markets 
AI
